On the other hand, real-world observational evidence has suggested that SGLT2-i use, compared with dipeptidyl peptidase-4 inhibitors use, may be associated with an even lower risk of hospitalizations due to genitourinary infections among patients with and without chronic kidney disease [58]. Here, SLC5A2 is linked to chronic kidney disease.